Welcome to our dedicated page for Elite Pharmaceuticals SEC filings (Ticker: ELTP), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Elite Pharmaceuticals, Inc. (ELTP) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures as filed with the U.S. Securities and Exchange Commission. Elite identifies itself in these filings as a Nevada corporation with common stock trading on the OTCQB under the symbol ELTP, and uses SEC reports to communicate material information about its operations, financial condition, and regulatory events.
Investors can review Elite’s annual reports on Form 10-K and quarterly reports on Form 10-Q for detailed discussions of its business as a specialty pharmaceutical company developing, manufacturing, and distributing niche generic products. These reports typically include information on product lines, such as immediate-release and controlled-release solid oral dose products, and descriptions of the company’s cGMP and DEA-registered facility in Northvale, New Jersey.
Elite also files current reports on Form 8-K to announce material events. Recent 8-K filings reference financial result press releases, conference call schedules, and FDA approval for a generic version of Requip XL (Ropinirole Extended-Release Tablets USP). Amendments on Form 8-K/A may be used to correct or clarify previously reported information, such as conference call dates.
Through Stock Titan, users can track ELTP filings as they are made available from EDGAR and use AI-powered summaries to interpret complex sections of lengthy documents. These tools can help clarify topics such as Elite’s revenue drivers, product and regulatory updates, and the significance of specific 8-K disclosures. For those monitoring ELTP, this page offers a structured way to follow the company’s official reporting history, from periodic reports to event-driven filings.
Elite Pharmaceuticals (ELTP) filed a Form 4 disclosing that EVP Operations Douglas Plassche sold common stock. On 10/02/2025, he executed a sale (code S) of 800,000 shares at a price of $0.624 per share. Following the transaction, he beneficially owns 3,500,000 shares, held directly.
The filing identifies the reporting person as an officer (EVP Operations) and indicates the ownership form as direct. No derivative securities transactions were reported in Table II.